Results from this trial will be presented in a webinar on Wednesday 23 February at 11.00am CET
Key points from this study:
• Achievement of the study’s primary endpoint, confirming glenzocimab’s
very favorable safety profile
• Reduction in the number of intracerebral hemorrhages and mortality
among patients treated with glenzocimab